# OnCo record paper-nct03851640-signal-transduct-target-ther-2026 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-nct03851640-signal-transduct-target-ther-2026/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-nct03851640-signal-transduct-target-ther-2026" ;
  schema:name "Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial"@en ;
  schema:description "Published report from the trial registered as NCT03851640, in Signal transduction and targeted therapy (2026), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-nct03851640-signal-transduct-target-ther-2026/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/s41392-026-02618-3>, <https://pubmed.ncbi.nlm.nih.gov/41968137/>, <https://europepmc.org/article/MED/41968137>, <https://clinicaltrials.gov/study/NCT03851640> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1038/s41392-026-02618-3> ;
  schema:datePublished "2026"^^xsd:gYear ;
  schema:author "Wu J, Li X, Gu C, et al." ;
  onco:trials <https://onco.cc/trials/nct03851640/> .